Nine Obesity Drugs Near Launch Could Break the GLP-1 Duopoly by 2027

From modeling GLP-1 drug trend across employer plan renewals for the past two years, every assumption built on current pricing could be obsolete within 18 months as nine competitors enter a market that has been a two-company duopoly. Oral Wegovy launched in January 2026. Eli Lilly's retatrutide reported 28.3% weight loss in pivotal trials with an NDA expected in Q4 2026. Amgen's MariTide targets a monthly dosing schedule with pivotal data in early 2027. Morningstar projects a 28% price decline as competition arrives. The actuarial question: how do you model drug trend when the cost curve could break in either direction within 12 months?

This is not a utilization story. Every outlet has covered GLP-1 costs as an access and adoption narrative. This article flips the lens to the supply side: what nine pipeline entrants mean for the pricing curve, and why actuaries need bifurcated trend scenarios that account for competitive disruption rather than just utilization growth.

The Current GLP-1 Market: A $132 Billion Duopoly Under Pressure

Through 2025, Novo Nordisk and Eli Lilly dominated the GLP-1 market in a manner rarely seen in modern pharmaceutical economics. Tirzepatide (Zepbound/Mounjaro) and semaglutide (Wegovy/Ozempic) each topped approximately $60 billion in annual spending, combining for roughly $132 billion. That single drug class accounted for nearly one-third of all growth in prescription drug spending in 2025, according to IQVIA data.

The concentration is worth internalizing. Two molecules, two manufacturers, and a combined spend that exceeds the entire GDP of several mid-sized countries. For health plan actuaries, this duopoly structure has made trend projection deceptively simple: model utilization growth, apply a stable per-unit cost assumption, and gross up for rebate erosion. That approach worked when pricing power was unchallenged. It will not survive 2027.

IQVIA's 2026 outlook characterizes this year as the shift "from consolidation to acceleration." Supply constraints that plagued the market in 2024 have largely resolved. The debut of oral GLP-1 formulations and the first loss of exclusivity for a GLP-1 receptor agonist are reshaping the competitive landscape. Within its first eight weeks on the U.S. market, oral Wegovy captured approximately one-third of new-to-brand prescriptions, a signal that pent-up demand for non-injectable options is substantial.

The financial scale is staggering. GLP-1 therapies now account for roughly 14% of all U.S. prescription drug spending, and total U.S. prescription spending is projected to cross $1 trillion in 2026. Evernorth's 2025 Pharmacy in Focus report documented GLP-1 net trend increases of 210.2% in 2023 and 148.7% in 2024, with a further 73.1% projected utilization increase for weight-loss indications through end of 2025. These are not normal trend factors. They represent a structural shift in the composition of the pharmacy benefit.

Pipeline Tracker: Nine Drugs That Could Reshape the Market

DelveInsight identified nine obesity drugs expected to reach market by 2027, and Prime Therapeutics' May 2026 pipeline update adds further granularity on regulatory timelines. Here is the competitive landscape that pricing actuaries need to model against.

Tier 1: Near-Term Market Entrants (2026 Launches or FDA Decisions)

Oral Wegovy (Novo Nordisk). FDA-approved and launched in the U.S. in January 2026. Once-daily oral semaglutide 25 mg demonstrated 16.6% mean weight loss in the OASIS 4 trial, comparable to the injectable 2.4 mg formulation. Novo Nordisk priced the oral version at approximately $149 per month for a cash-pay supply without insurance, with insured copays of $25 or less. This is a distribution and access play, not a clinical leap: same molecule, different route of administration, dramatically lower patient friction. From tracking formulary shifts, the one-third capture of new-to-brand prescriptions in the first eight weeks confirms that needle aversion was a meaningful utilization barrier that has now been removed.

Orforglipron (Eli Lilly). A once-daily oral non-peptide GLP-1 receptor agonist awaiting FDA decision by Q2 2026 for obesity and overweight. The ATTAIN-1 trial reported 11.2% mean body weight reduction at 72 weeks at the highest dose. If approved, this would give Lilly an oral competitor to Novo Nordisk's pill, intensifying price competition in the oral GLP-1 segment specifically.

Cagrisema (Novo Nordisk). A fixed-dose combination of semaglutide and cagrilintide (amylin analog), targeting additive weight loss beyond what semaglutide alone achieves. An NDA decision is expected in 2026, positioning Novo Nordisk to defend its franchise with a next-generation injectable.

Tier 2: Late-Stage Pipeline (NDA or Pivotal Readouts Expected Late 2026 Through Early 2027)

Retatrutide (Eli Lilly). The TRIUMPH-1 Phase 3 results, reported on May 21, 2026, represent the most significant clinical data point in this pipeline. In 2,339 adults with obesity or overweight, retatrutide 12 mg produced a mean weight loss of 28.3% (70.3 lbs / 31.9 kg) at 80 weeks. Among those continuing to 104 weeks, weight loss reached 30.3%. Critically, 45.3% of participants achieved at least 30% weight loss, a threshold that approaches bariatric surgery outcomes. Retatrutide is a first-in-class triple hormone receptor agonist activating GIP, GLP-1, and glucagon receptors simultaneously. Lilly is expected to file an NDA in Q4 2026. For actuaries, the clinical profile matters because drugs that deliver bariatric-level weight loss at pharmaceutical cost will expand the eligible population significantly beyond current utilization assumptions.

MariTide (Amgen). The MARITIME Phase 3 program includes MARITIME-1 (3,500 participants with obesity/overweight) and MARITIME-2 (999 participants with type 2 diabetes and obesity/overweight), with primary readouts expected in early 2027. MariTide's differentiator is its monthly dosing schedule, compared to the weekly injections required by most competitors. Phase 2 data showed up to 20% weight loss. Amgen is also exploring indications in cardiovascular disease, heart failure, kidney disease, and obstructive sleep apnea, which would broaden the covered population under medical benefit rather than pharmacy benefit coding.

Survodutide (Boehringer Ingelheim). A dual GLP-1/glucagon receptor agonist in late-stage development for obesity. Boehringer Ingelheim has been building out its metabolic pipeline, and survodutide adds another dual-agonist competitor to the landscape.

Tier 3: Mid-Stage Pipeline (Phase 2/3, Data Expected 2027)

VK2735 (Viking Therapeutics). An oral GLP-1/GIP dual agonist in Phase 2 development. Viking represents the class of smaller biotechs that could accelerate to market through licensing deals or acquisition, adding further competitive pressure.

CT-388 (Roche/Carmot). A once-weekly dual GLP-1/GIP receptor agonist acquired through Roche's $2.7 billion purchase of Carmot Therapeutics. Phase 2 data showed 22.5% weight loss at the highest dose by week 48. Roche has initiated Phase 3 trials and publicly stated its intention to become a top-three obesity player. Additionally, Roche has partnered with Zealand Pharma on petrelintide, a long-acting amylin analog, with plans to develop a fixed-dose combination of petrelintide and CT-388 starting in 2026.

Pemvidutide (Altimmune). A dual GLP-1/glucagon receptor agonist in development for obesity and metabolic dysfunction-associated steatohepatitis (MASH). The MASH crossover indication is notable because it could allow coding under medical rather than pharmacy benefits, altering the trend attribution channel.

Amycretin (Novo Nordisk). A novel amylin and GLP-1 co-agonist in development that represents Novo Nordisk's pipeline defense strategy beyond semaglutide.

Notably absent from this active list: Pfizer discontinued its oral GLP-1 candidate danuglipron after safety signals, including a case of possible liver damage. AstraZeneca is earlier in development with AZD5004 (Phase 2b) and recently signed a multi-program collaboration with CSPC Pharmaceuticals for once-monthly injectable assets, but neither is likely to reach market before 2028.

Obesity drugs expected to reach market by 2027 (DelveInsight), entering a market where two molecules control over $132 billion in annual spending

28.3%

Mean weight loss at 80 weeks in the TRIUMPH-1 trial of retatrutide (Eli Lilly), approaching bariatric surgery outcomes

28%

Morningstar's projected average obesity drug price decline in 2026 as competitive pressure and most-favored-nation dynamics take hold

The Pricing Cliff: How Competition Rewrites the Cost Curve

Morningstar's pricing model projects a 28% average obesity drug price drop in 2026, driven primarily by most-favored-nation pricing negotiations and TrumpRx provisions that leverage cash-pay channel dynamics. Net obesity drug prices are expected to fall from roughly $8,000 annually in 2025 to just under $6,000 in 2026, with a further trajectory to below $3,000 by 2034.

Novo Nordisk has already begun the price adjustment. In February 2026, the company announced it would lower the list price of Wegovy to $675 per month effective January 1, 2027, a reduction of approximately 50% from the prior list price of $1,349. Ozempic drops to the same $675, a 35% list price cut. Under the Inflation Reduction Act, Medicare's negotiated price for semaglutide products will be $274 per month starting January 1, 2027.

However, the list price cut deserves scrutiny. As Willis Towers Watson noted in its March 2026 analysis, Novo Nordisk is expected to offset lower list prices by reducing rebates, which means the net cost after all discounts may not change meaningfully for commercially insured plans. Mercer's follow-up analysis confirmed this dynamic: the list price reduction primarily benefits uninsured and cash-pay patients while leaving employer net costs approximately unchanged in the near term.

This is the pricing paradox that makes 2027 trend selection so difficult. List prices are falling. Net prices may not follow at the same rate. But a wave of new entrants will eventually force genuine net price competition because PBMs will have real alternatives to negotiate against. The question is timing.

Morningstar expects high-single-digit annual price declines following 2026, accelerating to 10% to 15% annual drops by 2027 and beyond as new entrants compete for formulary placement. If retatrutide, orforglipron, and CT-388 all reach market with competitive clinical profiles, PBMs will have leverage that does not exist today. A formulary with three or four therapeutically interchangeable options operates under fundamentally different economics than a formulary with two.

Bifurcated Trend Scenarios for 2027 Rate Filings

From tracking how the GLP-1 trend factor has reshaped employer plan pricing over the past year, the standard approach of selecting a single point estimate for pharmacy trend is increasingly inadequate for this drug class. Actuaries preparing 2027 rate filings should build bifurcated scenarios that explicitly model divergent supply-side outcomes.

Scenario A: Competition Materializes on Schedule

Under this scenario, retatrutide receives FDA approval in Q1 2027, orforglipron is approved by mid-2026, and MariTide pivotal data supports an NDA filing by late 2027. Three to four new entrants reach formulary negotiations by the 2027 renewal cycle. In this world:

Net per-unit GLP-1 cost declines 15% to 25% from 2026 levels as PBMs leverage formulary exclusion threats against multiple manufacturers
Utilization increases 20% to 30% year-over-year as broader coverage, oral formulations, and monthly dosing options reduce barriers to initiation
Net trend effect: roughly flat to modestly positive (5% to 10% increase) as unit cost declines partially offset utilization expansion
The EBRI simulation framework suggests employer premium increases in the 1% to 3.9% range under lower-priced GLP-1 assumptions ($200/month net cost)

Scenario B: Pipeline Delays Preserve Duopoly Pricing

Under this scenario, FDA regulatory delays push retatrutide approval to late 2027 or 2028, MariTide pivotal data shows a narrower efficacy gap than Phase 2 suggested, and PBMs lack the competitive alternatives needed to force meaningful net price concessions. In this world:

Net per-unit costs remain within 5% to 10% of current levels as Novo Nordisk and Eli Lilly maintain pricing discipline
Utilization still grows 25% to 40% as oral Wegovy and expanded indications (cardiovascular, MASH, sleep apnea) bring new patients into the GLP-1 class
Net trend effect: 30% to 50% pharmacy trend increase concentrated in the GLP-1 sub-category
Under EBRI's higher-cost assumptions, employer premium increases reach the 5.3% to 13.8% range depending on adherence and eligibility parameters

Weighting the Scenarios

The difference between these scenarios is not marginal. Scenario A implies that the GLP-1 cost problem begins to self-correct through market competition. Scenario B implies that 2027 is another year of compounding cost pressure with no relief valve. Given current regulatory timelines, a reasonable starting weight might be 40/60 favoring Scenario B for the 2027 plan year (the pipeline is promising but not yet approved), shifting to 60/40 favoring Scenario A for 2028 filings as approvals accumulate.

The EBRI simulation-based analysis provides a useful calibration framework. EBRI found that with current drug costs ($617 to $766 net per 30-day supply), premium increases ranged from 5.3% to 13.8% across adherence, cost-sharing, and eligibility assumptions. With a hypothetical lower-priced GLP-1 at $200 per month, increases dropped to 1% to 3.9%. The gap between those ranges is the pricing cliff that pipeline competition could trigger.

Employer and Plan Sponsor Response: Managing Through Uncertainty

Mercer's 2026 Survey on Health and Benefits Strategies found that 77% of large employers (500 or more employees) rank managing overall GLP-1 costs as extremely or very important. That finding sits alongside a coverage expansion trend: 44% of employers with 500 or more employees covered weight-loss medications in 2024, up from prior years, with the figure reaching 64% for employers with 20,000 or more workers.

From patterns we have seen in recent renewal cycles, employers are splitting into three strategic camps:

Wait-and-watch. Some sponsors are maintaining current coverage parameters while waiting for improved pricing through competition. This strategy bets on Scenario A materializing and treats current GLP-1 spend as a temporary premium on first-mover drugs. The risk is that if pipeline delays push competition out to 2028, sponsors absorb two more years of duopoly pricing.

Active management. Other sponsors are pairing GLP-1 coverage with mandatory lifestyle programs, prior authorization tightening, step-therapy requirements, or dispensing channel restrictions. The stop-loss carrier response to GLP-1 costs has accelerated this approach, as reinsurers increasingly require documented clinical management programs as a condition of renewal terms.

Carve-out and restrict. A smaller but growing segment is exploring dedicated GLP-1 vendor carve-outs that limit prescribing to specific pharmacy networks, or restricting coverage to diabetes-only indications while excluding weight management. The FDA's ban on compounded GLP-1s has removed what was previously an informal cost-management lever for some self-insured plans.

All three strategies share a common weakness: they are utilization-management responses to what is fundamentally a supply-side pricing problem. Until new entrants create genuine formulary competition, demand-side controls can slow cost growth but cannot reverse the trend trajectory. The pipeline is the structural solution.

Total Cost of Care: The 3-5 Year Offset Question

The most contentious assumption in GLP-1 trend modeling is whether short-term drug spending generates net savings over a multi-year horizon through reduced cardiometabolic events, fewer orthopedic procedures, and lower hospitalization rates. The evidence is building, but the timeframe for offset realization matters enormously for annual pricing cycles.

Aon's January 2026 research found that GLP-1 users experienced medical cost growth of just 3% over an 18-month period after initiating therapy, compared to 9% growth for a matched control group. Female GLP-1 users showed a 47% reduction in hospitalizations for major adverse cardiovascular events compared to female non-users. The therapies were also associated with lower rates of osteoporosis, rheumatoid arthritis, and fewer hospitalizations for bariatric surgery.

The clinical evidence continues to expand. Semaglutide gained FDA approval for metabolic dysfunction-associated fatty liver disease (MASH) and approval in chronic kidney disease. Tirzepatide received FDA approval for obstructive sleep apnea. In the TRIUMPH-1 trial, retatrutide demonstrated significant improvements in cardiovascular risk factors, including waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity C-reactive protein. Eli Lilly's SURPASS-CVOT trial showed an 8% reduction in major adverse cardiovascular events with tirzepatide versus dulaglutide.

For pricing actuaries, the challenge is temporal mismatch. Drug spending concentrates in Year 1. Cardiovascular event reduction takes 3 to 5 years to materialize in claims data. Orthopedic cost offsets (fewer knee replacements, reduced musculoskeletal claims) require even longer observation periods. The employer who covers GLP-1s today captures the drug cost immediately but may not retain the employee long enough to realize the medical offset.

This creates a collective action problem. The rational individual employer might restrict coverage to limit near-term cost exposure. But the health system as a whole benefits from broad coverage if the offset data holds. The CAA 2026 rebate passthrough mandate and potential federal PBM reform by 2029 could alter this calculus by making drug cost components more transparent, but they do not solve the temporal mismatch.

Modeling Framework: Decomposing GLP-1 Trend Into Four Components

Building on the 2026 MMI pharmacy trend decomposition approach, actuaries should isolate GLP-1 trend into discrete components rather than applying a blended pharmacy trend factor.

Component 1: Per-unit cost trajectory. Model separately for injectable and oral formulations. Injectable net costs currently range from $617 to $766 per 30-day supply (EBRI). Oral Wegovy enters at $149 cash-pay, but insured net costs will differ based on PBM contracting. Build a competitive-entry adjustment that reduces per-unit cost 5% per new entrant reaching formulary eligibility, with a floor set by the lowest-cost therapeutic equivalent.

Component 2: Utilization growth rate. Segment by indication (diabetes, obesity, cardiovascular, MASH) and route of administration (injectable, oral). Oral formulations will cannibalize some injectable volume while expanding the total addressable population. Over 40% of privately insured adults, more than 57 million people, are clinically eligible for GLP-1 drugs based on diagnoses of diabetes, obesity, or overweight with additional risk factors (EBRI). Current penetration is a fraction of that eligible population.

Component 3: Adherence and persistency. GLP-1 discontinuation rates remain high, typically 50% to 70% within the first year. Higher adherence improves clinical outcomes but increases plan spending in the short term. Pipeline drugs with less frequent dosing (monthly MariTide versus weekly injectables) may improve adherence, creating a paradoxical trend increase through better outcomes.

Component 4: Benefit channel migration. As GLP-1s gain approvals for cardiovascular disease, MASH, sleep apnea, and chronic kidney disease, claims may shift from pharmacy to medical benefit coding. This does not reduce total cost but changes which trend factor absorbs the spend. Actuaries pricing self-insured plans should model total cost of care rather than pharmacy trend in isolation.

Why This Matters for Health Plan Actuaries

The GLP-1 drug class has created a trend projection problem unlike anything actuaries have encountered in recent decades. The closest analogy is the introduction of protease inhibitors for HIV in the late 1990s, which generated enormous short-term pharmacy cost increases that were partially offset by dramatic reductions in hospitalization and mortality. But the GLP-1 eligible population is orders of magnitude larger than the HIV-positive population, and the cost offset timeline is longer and less certain.

Three specific implications for practice:

Trend assumption disclosure. Actuaries filing 2027 rates should explicitly disclose their GLP-1 pipeline assumptions. A rate filing that assumes continued duopoly pricing when nine competitors are in late-stage development lacks the conservatism that regulators expect. Conversely, a filing that assumes rapid price declines from pipeline competition bakes in risk if approvals are delayed. Disclosing the scenario weights and trigger events for revision is better practice than either extreme.

Reinsurance and stop-loss pricing. The catastrophic claim frequency surge in employer stop-loss markets is driven partly by GLP-1 costs stacking on top of other high-cost claims. If per-unit costs decline 15% to 25% under competition, the number of claimants exceeding specific deductible thresholds may actually increase as utilization expands, even as per-claimant cost decreases. Stop-loss actuaries need to model frequency and severity separately rather than applying a net trend factor.

Credibility weighting. For smaller employer groups with limited GLP-1 claims experience, the credibility-weighted trend selection described in the GLP-1 employer pricing framework becomes even more important. Plan-specific experience in a rapidly shifting market carries less predictive value than usual. Heavier weighting toward industry-wide trend benchmarks, adjusted for competitive-entry scenarios, may produce more stable rate indications.